Last reviewed · How we verify
Azelaic Acid 15% topical gel
At a glance
| Generic name | Azelaic Acid 15% topical gel |
|---|---|
| Also known as | Azelaic Acid |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel (PHASE1)
- A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily (PHASE4)
- A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face (PHASE2)
- A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis (PHASE2)
- Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea (PHASE3)
- Phase 3 Papulopustular Rosacea Study (PHASE3)
- Phase 3 Papulopustular Rosacea Study (PHASE3)
- A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azelaic Acid 15% topical gel CI brief — competitive landscape report
- Azelaic Acid 15% topical gel updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI